公开(公告)号：US20190144444A1

公开(公告)日：2019-05-16

申请号：US16191190

申请日：2018-11-14

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma Inc.

Inventor： James F. Blake ,  Laurence E. Burgess ,  Mark Joseph Chicarelli ,  James Gail Christensen ,  Adam Cook ,  Jay Bradford Fell ,  John P. Fischer ,  Matthew Arnold Marx ,  Macedonio J. Mejia ,  Pavel Savechenkov ,  Guy P.A. Vigers ,  Christopher Ronald Smith ,  Martha E. Rodriguez

IPC: C07D471/04 ,  C07D491/08 ,  A61P35/00

Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US10125134B2

公开(公告)日：2018-11-13

申请号：US15814279

申请日：2017-11-15

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma Inc.

Inventor： James F. Blake ,  Laurence E. Burgess ,  Mark Joseph Chicarelli ,  James Gail Christensen ,  Jay Bradford Fell ,  John P. Fischer ,  John J. Gaudino ,  Erik James Hicken ,  Ronald Jay Hinklin ,  Matthew Randolf Lee ,  Matthew Arnold Marx ,  Macedonio J. Mejia ,  Martha E. Rodriguez ,  Pavel Savechenkov ,  Tony P. Tang ,  Guy P. A. Vigers ,  Henry J. Zecca

IPC: C07D471/04 ,  C07D519/00 ,  A61K31/519

Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US09096567B2

公开(公告)日：2015-08-04

申请号：US14231356

申请日：2014-03-31

Applicant: Array BioPharma Inc.

Inventor： Laurence E. Burgess ,  Christopher T. Clark ,  Adam Cook ,  Christopher P. Corrette ,  Robert Kirk DeLisle ,  George A. Doherty ,  Kevin W. Hunt ,  Todd T. Romoff ,  Ganghyeok Kim

IPC: A61K31/352 ,  C07D311/04 ,  C07D311/58 ,  C07D405/12 ,  C07D407/12

CPC classification number: C07D311/58 ,  C07D311/04 ,  C07D405/12 ,  C07D407/12

Abstract: Provided herein is a method of treating an allergic inflammatory disease selected from asthma, dermatitis, allergic rhinitis, urticaria, anaphylaxis, angioedemea, allergies, contact hypersensitivity, drug hypersensitivity, and allergic conjunctivitis in a mammal, comprising administering a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof, to said mammal in need thereof, wherein A1, A2, W, L, G, R7a, R7b, R8, R9 and R10 are as defined herein.

Abstract translation: 本文提供了一种治疗哺乳动物中选自哮喘，皮炎，过敏性鼻炎，荨麻疹，过敏反应，血管紧张素，过敏，接触超敏反应，药物过敏和过敏性结膜炎的过敏性炎性疾病的方法，其包括给予治疗有效量的化合物 其中A1，A2，W，L，G，R7a，R7b，R8，R9和R10如本文所定义。

公开(公告)号：US20140221342A1

公开(公告)日：2014-08-07

申请号：US14231356

申请日：2014-03-31

Applicant: Array BioPharma Inc.

Inventor： Laurence E. Burgess ,  Christopher T. Clark ,  Adam Cook ,  Christopher P. Corrette ,  Robert Kirk DeLisle ,  George A. Doherty ,  Kevin W. Hunt ,  Todd T. Romoff ,  Ganghyeok Kim

IPC: C07D311/58 ,  C07D407/12 ,  C07D405/12

CPC classification number: C07D311/58 ,  C07D311/04 ,  C07D405/12 ,  C07D407/12

Abstract: Provided herein is a method of treating an allergic inflammatory disease selected from asthma, dermatitis, allergic rhinitis, urticaria, anaphylaxis, angioedemea, allergies, contact hypersensitivity, drug hypersensitivity, and allergic conjunctivitis in a mammal, comprising administering a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof, to said mammal in need thereof, wherein A1, A2, W, L, G, R7a, R7b, R8, R9 and R10 are as defined herein.

Abstract translation: 本文提供了一种治疗哺乳动物中选自哮喘，皮炎，过敏性鼻炎，荨麻疹，过敏反应，血管紧张素，过敏，接触超敏反应，药物过敏和过敏性结膜炎的过敏性炎性疾病的方法，包括给予治疗有效量的化合物 其中A1，A2，W，L，G，R7a，R7b，R8，R9和R10如本文所定义。

公开(公告)号：US20140142086A1

公开(公告)日：2014-05-22

申请号：US14016951

申请日：2013-09-03

Applicant: ARRAY BIOPHARMA, INC. ,  VENTIRX PHARMACEUTICALS, INC.

Inventor： James Jeffry Howbert ,  Gregory Dietsch ,  Robert M. Hershberg ,  Laurence E. Burgess ,  George A. Doherty ,  C. Todd Eary ,  Robert D. Groneberg ,  Zachary Jones

IPC: C07D403/14 ,  C07D223/16 ,  C07D401/04 ,  C07D403/04 ,  C07D403/10 ,  C07D401/14

CPC classification number: C07D223/16 ,  A61K31/4025 ,  A61K31/55 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D403/10 ,  C07D403/14

Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.